Skip to content

Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve

Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve: A Potential New Therapeutical Intervention for Shortening Postoperative Ileus

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02524626
Enrollment
130
Registered
2015-08-17
Start date
2017-07-01
Completion date
2019-12-31
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Ileus

Keywords

Vagus nerve stimulation, Postoperative ileus

Brief summary

Hypothesis: Electrical stimulation of the abdominal vagus nerve has anti-inflammatory effects which lead to a faster postoperative recovery after abdominal surgery. Aims: In the present study, the investigators want evaluate the anti-inflammatory effect of peroperative electrical stimulation of the vagus nerve. In addition, the investigators want to determine whether vagus nerve stimulation leads to a faster postoperative recovery. To this end, the following aims are formulated: 1. to determine whether vagus nerve stimulation leads to an improvement in gastrointestinal transit using radiological testing 2. to evaluate whether electrical stimulation of the vagus nerve leads to clinical improvement (daily questionnaire) 3. to show that electrical stimulation of the intra-abdominal vagus nerve reduces the inflammatory response to abdominal surgery

Interventions

PROCEDURESham stimulation

Sham stimulation

Vagus stimulation

Sponsors

Universitaire Ziekenhuizen KU Leuven
CollaboratorOTHER
KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with ovarium, pancreas or colorectal carcinoma eligible for resection

Exclusion criteria

* preoperative therapeutic abdominal radiation shorter than 2 weeks prior to surgery * evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory test results, including abscess or cholecystitis) * American Society of Anesthesiologists physical-health status classification (ASA-PS) \> 3 * poorly regulated diabetes (\> 200 mg/dl (= 11 mmol/l) * surgery due to chronic pancreatitis

Design outcomes

Primary

MeasureTime frame
The gastrointestinal transit (geometric mean)From postoperative day 3 until postoperative day 7

Secondary

MeasureTime frame
Time to first flatusFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to tolerance of oral food intakeFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to tolerance of oral food intake and first defecationFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Gastric stasis (volume of gastric fluid produced by gastric tube on postoperative day 1From the date of surgery until postoperative day 1
Gastrointestinal symptoms (nausea, pain, vomiting, bloating)From the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to discharge from the hospitalFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Levels of pro-inflammatory cytokines in intestinal tissue, serum, peritoneal lavage and supernatant of stimulated whole bloodFrom the date of surgery until the date of lab analysis (up to 6 months)
Time to first defecationFrom the date of surgery until the date of discharge from the hospital (on average 14 days)

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026